P53 Codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern chinese population

Urologia Internationalis

Volumn 85, Issue 4, 2010, Pages 401-405

  Xu, Bin ^a,b   Mi, Yuan Yuan ^a   Min, Zhi Chao ^a   Cheng, Gong ^a   Tong, Na ^b   Tao, Jun ^a   Li, Peng Chao ^a   Wang, Mei Lin ^b   Tang, Jia Lin ^b   Zhang, Zheng Dong ^b   Song, Ning Hong ^a   Zhang, Wei ^a   Wu, Hong Fei ^a   Feng, Ning Han ^a   Hua, Li Xin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Biochemical recurrence; MDM2; p53; Polymorphism; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN MDM2; PROTEIN P53;

AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHINESE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GLEASON SCORE; HUMAN; MALE; POLYMERASE CHAIN REACTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CHINA; CODON; DISEASE-FREE SURVIVAL; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHENOTYPE; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650966277     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315991     Document Type: Article

References (14)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249
2. Gu F: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in china. Chin Med J (Engl) 2000; 113: 299-302
3. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical diseasefree and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-565
4. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439 (Pubitemid 41124175)
5. Hallstrom TM, Laiho M: Genetic changes and DNA damage responses in the prostate. Prostate 2008; 68: 902-918
6. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-860
7. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, et al: NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8: 162-200
8. Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50: 125-128
9. Huang SP, Huang CY, Wang JS, Liu CC, Pu YS, Yu HJ, et al: Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. Clin Cancer Res 2007; 13: 6632-6638
10. Hirata H, Hinoda Y, Kikuno N, Suehiro Y, Shahryari V, Ahmad AE, et al: Bcl2 -938c/a polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol 2009; 181: 1907-1912
11. Bond GL, Hu W, Levine A: A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005; 65: 5481-5484
12. Wang M, Zhang Z, Zhu H, Fu G, Wang S, Wu D, et al: A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a chinese population. Clin Cancer Res 2008; 14: 3633-3640
13. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, et al.: MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006; 24: 4434-4440
14. Jaboin JJ, Hwang M, Perez CA, Cooper C, Chen H, Ye C, et al: No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes. Urol Oncol DOI: 10.1016/j.urolonc.2009.03. 031